Evidence map›Paper›PMID 32690803›Full record

SynthesisJournal of neurology, neurosurgery, and psychiatry2020

Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials.

Jin-Tai Yu, Wei Xu, Chen-Chen Tan, Sandrine Andrieu, John Suckling, Evangelos Evangelou, An Pan, Can Zhang, Jianping Jia, Lei Feng and 15 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of neurology, neurosurgery, and psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 246 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
246citing papers in PubMed, 17 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

246 citing papers in PubMed, 17 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Non-Genetic Risk Factors of Alzheimer's Disease: An Updated Umbrella Review.The journal of prevention of Alzheimer's disease · 2024
    Pooled it
  10. Pooled it
  11. A Systematic Review of the Effects of Capsaicin on Alzheimer's Disease.International journal of molecular sciences · 2023
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Trial

186 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Jin-Tai Yu *Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China jintai_yu@fudan.edu.cn.ORCID 0000-0002-7686-0547
Wei Xu *Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.ORCID 0000-0002-3310-5875
Chen-Chen Tan *Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Sandrine AndrieuDepartment of Epidemiology and Public Health, University of Toulouse III, Toulouse, France.
John SucklingDepartment of Psychiatry, Medical Research Council and Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
Evangelos EvangelouDepartment of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece.
An PanDepartment of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Can ZhangDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Jianping JiaDepartment of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China.
Lei FengDepartment of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Ee-Heok KuaDepartment of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Yan-Jiang WangDepartment of Neurology, Daping Hospital, Third Military Medical University, Chongqing, China.
Hui-Fu WangDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Meng-Shan TanDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Jie-Qiong LiDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Xiao-He HouDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Yu WanDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Lin TanDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Vincent MokDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Lan TanDepartment of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Qiang DongDepartment of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Jacques TouchonDepartment of Neurology, University Hospital of Montpellier, Montpellier, France.
Serge GauthierMcGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada.
Paul S AisenAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Bruno VellasDepartment of Geriatrics, Purpan University Hospital, Toulouse, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvidence on preventing Alzheimer's disease (AD) is challenging to interpret due to varying study designs with heterogeneous endpoints and credibility. We completed a systematic review and meta-analysis of current evidence with prospective designs to propose evidence-based suggestions on AD prevention.

methodsElectronic databases and relevant websites were searched from inception to 1 March 2019. Both observational prospective studies (OPSs) and randomised controlled trials (RCTs) were included. The multivariable-adjusted effect estimates were pooled by random-effects models, with credibility assessment according to its risk of bias, inconsistency and imprecision. Levels of evidence and classes of suggestions were summarised.

resultsA total of 44 676 reports were identified, and 243 OPSs and 153 RCTs were eligible for analysis after exclusion based on pre-decided criteria, from which 104 modifiable factors and 11 interventions were included in the meta-analyses. Twenty-one suggestions are proposed based on the consolidated evidence, with Class I suggestions targeting 19 factors: 10 with Level A strong evidence (education, cognitive activity, high body mass index in latelife, hyperhomocysteinaemia, depression, stress, diabetes, head trauma, hypertension in midlife and orthostatic hypotension) and 9 with Level B weaker evidence (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, cerebrovascular disease, frailty, atrial fibrillation and vitamin C). In contrast, two interventions are not recommended: oestrogen replacement therapy (Level A2) and acetylcholinesterase inhibitors (Level B).

interpretationEvidence-based suggestions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD.

Indexed as

Evidence-Based MedicineAlzheimer DiseaseAntihypertensive AgentsCognitionCraniocerebral TraumaDepressionDiabetes MellitusEducationExerciseHumansHyperhomocysteinemiaHypertensionHypotension, OrthostaticLife StyleObesityObservational Studies as TopicAntihypertensive Agentsalzheimer's diseaseepidemiologymeta-analysissystematic reviews

Identifiers

PMID32690803
PMCPMC7569385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.